Preclinical evaluation of cilnidipine nanosponges for enhanced oral bioavailability and sustained antihypertensive efficacy.

Suryawanshi A, Ratnaparkhi M, Shinde R

Open source

DOI
10.1016/j.pharma.2026.05.010
Published
2026 May 30
Container
Annales pharmaceutiques francaises
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.pharma.2026.05.010,
  title = {Preclinical evaluation of cilnidipine nanosponges for enhanced oral bioavailability and sustained antihypertensive efficacy.},
  author = {Suryawanshi A and Ratnaparkhi M and Shinde R},
  year = {2026},
  journal = {Annales pharmaceutiques francaises},
  doi = {10.1016/j.pharma.2026.05.010},
  url = {https://doi.org/10.1016/j.pharma.2026.05.010}
}

RIS

TY  - JOUR
TI  - Preclinical evaluation of cilnidipine nanosponges for enhanced oral bioavailability and sustained antihypertensive efficacy.
AU  - Suryawanshi A
AU  - Ratnaparkhi M
AU  - Shinde R
PY  - 2026
JO  - Annales pharmaceutiques francaises
DO  - 10.1016/j.pharma.2026.05.010
UR  - https://doi.org/10.1016/j.pharma.2026.05.010
ER  - 

APA

A, S., M, R., & R, S. (2026). Preclinical evaluation of cilnidipine nanosponges for enhanced oral bioavailability and sustained antihypertensive efficacy.. Annales pharmaceutiques francaises. https://doi.org/10.1016/j.pharma.2026.05.010

Source records